Literature DB >> 24867256

Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease.

Valtteri Kaasinen1, Maija Kinos, Juho Joutsa, Marko Seppänen, Tommi Noponen.   

Abstract

PURPOSE: Parkinson's disease (PD) can manifest with a tremor-dominant or a non-tremor (akinetic-rigid) phenotype. Although the tremor-dominant subtype may show a better prognosis, there is limited information on the phenotypic differences regarding the level of striatal dopamine transmission. The present study investigated striatal dopamine transporter (DAT) binding characteristics in a large sample of patients with and without tremor.
METHODS: [(123)I]FP-CIT SPECT scans of 231 patients with a clinical diagnosis of PD and abnormal FP-CIT binding (157 with tremor, 74 without tremor) and 230 control patients with normal FP-CIT binding (148 with tremor, 82 without tremor) were analysed using an automated region-of-interest analysis of the scans (BRASS). Specific striatal binding ratios were compared between phenotypes and groups using age, sex, and symptom duration, predominant side of symptoms, dopaminergic medications and scanner as covariates.
RESULTS: Patients with PD had 28.1 - 65.0 % lower binding in all striatal regions compared to controls (p < 0.001). The mean FP-CIT caudate nucleus uptake and the left caudate nucleus uptake were higher in PD patients with tremor than in PD patients without tremor (mean 9.0 % higher, left 10.5 % higher; p < 0.05), whereas there were no differences between tremor and non-tremor control patients. No significant effects of tremor on DAT binding were observed in the anterior or posterior putamen.
CONCLUSION: The motor phenotype is associated with the extent of caudate dopamine terminal loss in PD, as dopamine function is relatively more preserved in tremor patients. Symptom type is related to caudate dopamine function only in association with Parkinsonian dopaminergic degeneration, not in intact dopamine systems in patients with non-PD tremor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24867256     DOI: 10.1007/s00259-014-2796-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  36 in total

1.  Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson's disease.

Authors:  Alexei Korchounov; Hayo I Schipper; Irina S Preobrazhenskaya; Kirn R Kessler; Nikolay N Yakhno
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

2.  Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT.

Authors:  O Schillaci; A Chiaravalloti; M Pierantozzi; B Di Pietro; G Koch; C Bruni; P Stanzione; A Stefani
Journal:  Int J Mol Med       Date:  2011-08-02       Impact factor: 4.101

Review 3.  Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease.

Authors:  Valtteri Kaasinen; Juha O Rinne
Journal:  Neurosci Biobehav Rev       Date:  2002-11       Impact factor: 8.989

4.  Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.

Authors:  Minyoung Oh; Jae Seung Kim; Ji Young Kim; Kwang-Ho Shin; Seol Hoon Park; Hye Ok Kim; Dae Hyuk Moon; Seung Jun Oh; Sun Ju Chung; Chong Sik Lee
Journal:  J Nucl Med       Date:  2012-02-09       Impact factor: 10.057

5.  Differences in brain activation between tremor- and nontremor-dominant Parkinson disease.

Authors:  Janey Prodoehl; Peggy J Planetta; Ajay S Kurani; Cynthia L Comella; Daniel M Corcos; David E Vaillancourt
Journal:  JAMA Neurol       Date:  2013-01       Impact factor: 18.302

6.  How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale.

Authors:  Glenn T Stebbins; Christopher G Goetz; David J Burn; Joseph Jankovic; Tien K Khoo; Barbara C Tilley
Journal:  Mov Disord       Date:  2013-02-13       Impact factor: 10.338

Review 7.  Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools.

Authors:  R M Liscic; K Srulijes; A Gröger; W Maetzler; D Berg
Journal:  Acta Neurol Scand       Date:  2013-02-13       Impact factor: 3.209

8.  An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.

Authors:  In-Uk Song; Yong-An Chung; Jin-Kyoung Oh; Sung-Woo Chung
Journal:  Acta Radiol       Date:  2013-08-13       Impact factor: 1.990

Review 9.  Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?

Authors:  Rick C Helmich; Mark Hallett; Günther Deuschl; Ivan Toni; Bastiaan R Bloem
Journal:  Brain       Date:  2012-03-01       Impact factor: 13.501

Review 10.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

Authors:  C H Williams-Gray; T Foltynie; C E G Brayne; T W Robbins; R A Barker
Journal:  Brain       Date:  2007-05-29       Impact factor: 13.501

View more
  12 in total

1.  Structural connectivity differences in motor network between tremor-dominant and nontremor Parkinson's disease.

Authors:  Gaetano Barbagallo; Maria Eugenia Caligiuri; Gennarina Arabia; Andrea Cherubini; Angela Lupo; Rita Nisticò; Maria Salsone; Fabiana Novellino; Maurizio Morelli; Giuseppe Lucio Cascini; Domenico Galea; Aldo Quattrone
Journal:  Hum Brain Mapp       Date:  2017-06-20       Impact factor: 5.038

2.  Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease.

Authors:  Marcello Moccia; Sabina Pappatà; Marina Picillo; Roberto Erro; Anna Rita Daniela Coda; Katia Longo; Carmine Vitale; Marianna Amboni; Arturo Brunetti; Giuseppe Capo; Marco Salvatore; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2014-08-14       Impact factor: 4.849

3.  Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.

Authors:  Elina Mäkinen; Juho Joutsa; Jarkko Johansson; Maija Mäki; Marko Seppänen; Valtteri Kaasinen
Journal:  J Neural Transm (Vienna)       Date:  2016-06-20       Impact factor: 3.575

4.  Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders.

Authors:  Elon D Wallert; Elsmarieke van de Giessen; Remco J J Knol; Martijn Beudel; Rob M A de Bie; Jan Booij
Journal:  J Nucl Med       Date:  2022-06       Impact factor: 11.082

Review 5.  Therapy-resistant symptoms in Parkinson's disease.

Authors:  Ruxandra Julia Vorovenci; Roberta Biundo; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2015-09-26       Impact factor: 3.575

6.  Predictors of normal and abnormal outcome in clinical brain dopamine transporter imaging.

Authors:  Elina Jaakkola; Juho Joutsa; Valtteri Kaasinen
Journal:  J Neural Transm (Vienna)       Date:  2015-12-16       Impact factor: 3.575

7.  Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson's disease subtype.

Authors:  Ismael Huertas; Silvia Jesús; José Antonio Lojo; Francisco Javier García-Gómez; María Teresa Cáceres-Redondo; Juan Manuel Oropesa-Ruiz; Fátima Carrillo; Laura Vargas-Gonzalez; Juan Francisco Martín Rodríguez; Pilar Gómez-Garre; David García-Solís; Pablo Mir
Journal:  PLoS One       Date:  2017-03-30       Impact factor: 3.240

Review 8.  Neuroimaging Detectable Differences between Parkinson's Disease Motor Subtypes: A Systematic Review.

Authors:  Jackson Tyler Boonstra; Stijn Michielse; Yasin Temel; Govert Hoogland; Ali Jahanshahi
Journal:  Mov Disord Clin Pract       Date:  2020-11-06

9.  Factors associated with motor complications in Parkinson's disease.

Authors:  Liis Kadastik-Eerme; Nele Taba; Toomas Asser; Pille Taba
Journal:  Brain Behav       Date:  2017-09-25       Impact factor: 2.708

10.  Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT.

Authors:  Elina Mäkinen; Juho Joutsa; Elina Jaakkola; Tommi Noponen; Jarkko Johansson; Miia Pitkonen; Reeta Levo; Tuomas Mertsalmi; Filip Scheperjans; Valtteri Kaasinen
Journal:  J Neurol       Date:  2019-01-28       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.